OSE Immunotherapeutics SA (OSE.PA) Comparison with companies in other sectors?

OSE Immunotherapeutics SA has a share price of 22.87M. You can analyze OSE Immunotherapeutics SA (OSE.PA) competitors across different market sectors through stock heatmaps.

What are OSE.PA's NET and operating margins?

OSE Immunotherapeutics SA (OSE.PA) operating margin is around 0.38, and net profit margin is approximately 0.54 as of the latest reports.

In what way does OSE.PA's earnings per share (EPS) trend reflect its financial momentum?

OSE Immunotherapeutics SA (OSE.PA) EPS is 1.46 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for OSE Immunotherapeutics SA is 4.30, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for OSE Immunotherapeutics SA?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for OSE Immunotherapeutics SA like P/E which is 3.63, P/B which is 2.13, and PEG which is -0.21. Compare them with sector averages to evaluate if the stock is priced fairly.

OSE Immunotherapeutics SA

OSE.PA•EURONEXT

Healthcare

Biotechnology

€6.28

€0.46(8.00%)

Fundamental Analysis of OSE Immunotherapeutics SA (OSE.PA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.46

P/E Ratio

4.30

ROE

0.52%

Net Margin

0.54%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$143.61M

Shares OutstandingTotal number of shares issued

$22.87M

Book Value/ShareNet worth per share

$2.95

Revenue/ShareAnnual revenue per share

$3.23

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.46

Net MarginNet income as percentage of revenue

53.59%

Operating MarginOperating income as percentage of revenue

37.93%

ROEReturn on shareholders' equity

51.56%

ROAReturn on total assets

30.21%

ROCEReturn on capital employed

25.55%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.23

Cash/ShareCash and equivalents per share

$0.77

FCF YieldFree cash flow as percentage of market cap

33.68%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for OSE.PAFinancial Ratios Analysis details for OSE.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for OSE.PASector Benchmarking details for OSE.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for OSE Immunotherapeutics SA Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of OSE Immunotherapeutics SA. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account OSE Immunotherapeutics SA's unique business strengths and challenges.

Key Financial Metrics for OSE Immunotherapeutics SA

For OSE Immunotherapeutics SA, essential financial indicators include EPS 1.46, PE 4.30, and ROE 0.52. These key ratios reveal insights into OSE Immunotherapeutics SA's profitability, valuation, and operational health. Understanding these metrics enables you to compare OSE Immunotherapeutics SA with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of OSE Immunotherapeutics SA

Metrics like Net Margin 53.59% and ROA 30.21% shed light on how well OSE Immunotherapeutics SA is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether OSE Immunotherapeutics SA can sustain its operations and continue growing in the future.

Valuation and Market Position of OSE Immunotherapeutics SA

Using ratios such as P/B Ratio 2.13 and PEG Ratio -0.21, investors can assess whether OSE Immunotherapeutics SA is appropriately valued based on its financials and growth potential. These figures, combined with OSE Immunotherapeutics SA's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for OSE Immunotherapeutics SA

Financial health indicators, such as Debt/Equity Ratio 0.72 and Cash Flow $2.23, provide a snapshot of OSE Immunotherapeutics SA's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like OSE Immunotherapeutics SA, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for OSE Immunotherapeutics SA

Investing in OSE Immunotherapeutics SA based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at OSE Immunotherapeutics SA focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;